The growth of the global Cardiac pacemaker market is majorly driven by an increase in demand for minimally invasive procedures, a rise in funding from private & government organizations for the healthcare sector, and a rise in the prevalence of cardiovascular diseases. According to Drugs & Diseases, in April 2021, it was reported that the permanent pacemaker insertion technique is considered a minimally invasive procedure. Thus, the rise in demand for minimally invasive surgical procedures and increase in the adoption of cardiac surgical procedures such as endocardial or epicardial for the implantation of pacemakers drive the growth of the global market. For instance, in 2020, Abbott Laboratories, an American multinational medical device, and healthcare company has spent $2.42 billion in the R&D sector.